Enforcement Report - Week of February 22, 2023
Mundipharma and Cidara Therapeutics have presented data from the Phase III ReSTORE trial of rezafungin, in the treatment of candidemia and/or invasive candidiasis.
UBI's Generic Caspofungin Acetate Receives Approval in the US
As Bayer management predicted, it seems as though the German conglomerate’s for-sale animal health business has indeed attracted high interest. China’s Fosun International, parent of Fosun Pharma, is considering teaming up with private equity firms or other investors for a joint offer for Bayer’s animal health business, Bloomberg reported, citing people familiar with the matter.
The first data readout from a phase 3 trial of Scynexis’ ibrexafungerp has come in, and at first glance looks very positive for the first-in-class antifungal.
British F2G Biotech bags €24m
A supply disruption alert was issued by the Department of Health & Social Care (DHSC) on EpiPen and EpiPen Junior; see MHRA advice on extension of use beyond the expiry date for certain batches of EpiPen 300 microgram adrenaline autoinjectors. MHRA issued alerts and recalls for batches of Olmetec, Mydriasert, Caspofungin, and Imatinib.
A supply disruption alert was issued by the Department of Health & Social Care (DHSC) on EpiPen and EpiPen Junior; see MHRA advice on extension of use beyond the expiry date for certain batches of EpiPen 300 microgram adrenaline autoinjectors. MHRA issued alerts and recalls for batches of Olmetec, Mydriasert, Caspofungin, and Imatinib.
A supply disruption alert was issued by the Department of Health & Social Care (DHSC) on EpiPen and EpiPen Junior; see MHRA advice on extension of use beyond the expiry date for certain batches of EpiPen 300 microgram adrenaline autoinjectors. MHRA issued alerts and recalls for batches of Olmetec, Mydriasert, Caspofungin, and Imatinib.
Cipla`s Generic Caspofungin Acetate Receives Approval in US